Key Points:
- Sudeep Pharma IPO GMP: Grey market premium of ₹130 suggests a ~₹723 listing price.
- Retail investors get 35% allocation; one lot costs ₹14,825.
- Funds will be used for machinery expansion and corporate needs.
The Sudeep Pharma IPO will open for public subscription on Friday, Nov. 21. The speciality chemicals and ingredients manufacturer aims to raise funds through a combination of a fresh issue and an offer for sale. The company has set a price band of ₹563 to ₹593 per share.
Price Band Details
Sudeep Pharma plans to issue about 16 lakh fresh shares and conduct an offer for sale of nearly 1.35 crore shares. The IPO will remain open until Tuesday, Nov. 25.
Market participants said the grey market showed a premium of ₹130 on Nov. 20. Based on the upper end of the price band, the premium indicates an estimated listing price of ₹723, which reflects an upside of nearly 22 percent.
Subscription Structure
Half of the net issue is reserved for qualified institutional buyers. Retail investors will have access to 35 percent of the issue, and non-institutional investors will get 15 percent. The minimum lot size is 25 shares. At the upper price band, retail investors need ₹14,825 for one lot. The maximum lot size for retail participants is 13, requiring an investment of ₹1,92,725.
ICICI Securities and IIFL Capital Services Limited are the book-running lead managers. MUFG Intime India Private Limited will serve as the registrar.
Key Dates and Listing
The IPO will close on Tuesday, Nov. 25. The company expects to finalise share allotments on Wednesday, Nov. 26. Successful applicants are likely to receive shares on Thursday, Nov. 27, while refunds for unsuccessful bidders will also be processed the same day. Sudeep Pharma plans to list on the BSE and the NSE on Friday, Nov. 28.
Fund Utilisation
Sudeep Pharma said it will use the net proceeds for capital expenditure, principally to procure machinery for its production line at Nandesari Facility I. The remaining amount will go toward general corporate purposes under the Sudeep Pharma IPO.
Business Overview
Sudeep Pharma manufactures excipients and speciality ingredients for the pharmaceutical, food, and nutrition sectors. The company operates in several international markets, including the US, South America, Europe, the Middle East, Africa, and Asia-Pacific.
Financial Performance
The company reported steady growth over the past three financial years. Profit rose from ₹62.32 crore in FY23 to ₹133.19 crore in FY24, then to ₹138.69 crore in FY25. For the first quarter of FY26, profit stood at ₹30.81 crore.
Revenue from operations increased from ₹428.74 crore in FY23 to ₹459.28 crore in FY24. It reached ₹502 crore in FY25. For the quarter ended June 30, 2025, revenue was ₹124.92 crore.
The Sudeep Pharma IPO enters the market amid strong investor interest, backed by consistent financial growth and active grey market participation. The subscription window, pricing details, and allocation schedule position the issue as one of the key offerings in November’s primary market lineup.
Visit Business Viewpoint Magazine For The Most Recent Information.
